A revised framework for global medicine access Sanjay Basu Reblaw X.

Slides:

Advertisements

Similar presentations

Caribbean Central American Action (CCAA) Strengthening in the Third Border (CBI) CCA 27 th Annual Miami Conference on the Caribbean Basin Dr Rosanna Cooper,

Advertisements

TRIPs and Public Health: The Unresolved Debate Tenu Avafia tralac

Intellectual property rights and procurement = international developments & national experiences = Bi-regional Workshop on procurement and supply management.

Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.

1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.

Understanding patents & medicine access the WTO, free trade agreements & patent law.

Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.

Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.

Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.

PART FOUR: CANADA AND THE WORLD 9. Canada and Global Trade 10. Canada and Europe* 11. Official Development Assistance 12. Canada and the Asia-Pacific*

6.3. The Politics of the Global Economy Learning Objectives: –Familiar with the structures of global economic management –Identify the role and function.

Medicine Access: Claims & Data Sanjay Basu. The Framework for Access The pipeline fallacy Patents and pricing.

Greedy Sleazy Patent Owners vs. Poor Sick People International Patent Protection and Access to Drugs in the Third World Liz Durham November 4, 2003.

© 2011 Cengage Learning. All Rights Reserved. May not be scanned, copied or duplicated, or posted to a publicly accessible website, in whole or in part.

The Politics of Patents Jason Andrews. The Access GAP 2.4 Million people died of AIDS in sub Saharan Africa in 2002 – yet only 50,000 in the region had.

Intellectual Property Rights, Services and Trade Facilitation CARSTEN FINK African/LDCs Ambassadors Seminar on Post-Hong Kong Assessment of the Doha Round,

Policy Issues Concerning Parallel Trade of Pharmaceutical Drugs in the United States James Love CPTech FDA Prescription Drug Importation Meeting 14 April.

1 ICC and AIPLA Paris, September 13, 2002 Felix Addor Chief Legal Officer and Deputy Director General Swiss Federal Institute of Intellectual Property.

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

A very short introduction to patents & access to medicines.

Globalization and International Linkages

Access to Essential Medicines and Intellectual Property Rights in Developing Countries Rachel M. Cohen Access to Essential Medicines Campaign Doctors Without.

Washington D.C., USA, July 2012www.aids2012.org Intellectual Property-related challenges: A Latin America Perspective GraciaVioleta Ross

Public health, innovation and intellectual property 1 |1 | Dr Germán Velásquez Director WHO Secretariat Public Health, Innovation and Intellectual Property.

Why is protecting pharmaceutical patents a controversial issue in DCs? Poor DCs can neither produce nor afford to buy patented drugs. They need generic.

TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.

Restrictions on exports of medicine: irrational public policy, backdoor efforts to marginalize compulsory licensing, or Northern protectionism? James Love.

1 Investing in Innovation Should the EU do more to match US investment in innovative medicines? Brian Ager EFPIA Gastein, 6 October 2004.

D OHA N EGOTIATIONS & I NDIA P resenters * E vgeniya Burova * M ohini Patel.

Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?

TRIPS plus FTAs Rohit Malpani Oxfam America. Public health consequences of TRIPS plus FTAs Prospective studies on FTAs with TRIPS plus provisions –US.

Trade-related policies and access to medicines ICTSD Consultation on trade policy coherence and access to medicines Geneva November 7 th 2006,

WHO Perspective on Medicine Patents and FTAs Asian Regional Workshop on FTAs August, 2005, Kuala Lumpur, Malaysia Dr Zafar Mirza Regional Adviser,

1 CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur Session 10.

Intellectual Property Rights in the WTO CARSTEN FINK The WTO and the Doha Development Agenda Washington, DC, April 26, 2005.

Page 1 Implementation of the WTO Decision on TRIPS and Public Health Government of Canada August 2004.

UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.

© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.

Unit 7 -TRADE International Trade Vocabulary Free Trade Trade Barriers

Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?

Copyright © 2005 by South-Western, a division of Thomson Learning, Inc. All rights reserved. 1-1 Competing in Global Markets.

TRIPS TRIPS is the Agreement on Trade Related Aspects of Intellectual Property Rights Framed within the WTO, by “consensus” Regulates intellectual property.

Past, present and future. The benefits of enlarging the Union to include these countries are political, economic, and cultural: The extension.

WTO and the TRIPS Agreement Wolf R. MEIER-EWERT WTO Secretariat A Business-oriented overview of Intellectual Property for Law Students WIPO, Geneva 20.

Access to Medications: An introduction Braveen Ragunanthan Keanan McGonigle Slides prepared by: Alison Case, Education and Advocacy Fellow Katrina Ciraldo,

INT 200: Global Capitalism and its Discontents The Global Economic Order.

South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.

Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.

WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.

Regional Alliances Common interests.

WTO Status of Negotiation, July 2004 Framework... and Beyond Debra Henke USDA/ Foreign Agricultural Service.

Implications of the TRIPS Patent Policy Srividhya Ragavan University of Oklahoma Law Center.

TRIPS-Plus Pressures: Trade Agreements, and New Trade Policy Prof. Brook K. Baker OSI Kiev – IPRs & A2M, Sept. 16, 2009.

The Global Drug Gap: Access Inequities and Policy Implications Michael R. Reich Harvard School of Public Health International Conference on Pharmacoepidemiology.

The Inequals of Uruguay Srividhya Ragavan University of Oklahoma College of Law.

AIDS DRUGS, NATIONAL EMERGENCY & CIPRO Srividhya Ragavan Nat. Academy For Legal Studies & Research.

NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.

1 Special mechanism for the importation of pharmaceutical products under the TRIPS Agreement Carlos M. Correa.

TRADE NEGOTIATION ON PHARMACETICALS PRESENTED BY CHOGO,MALESO (092SIS10).

Human Rights and Access to Medicines Sean Flynn AU, Washington College of Law Abuja, Nigeria, November 2008.

M Forere, lecturer - UKZN.  Tariffs imposed on imports – trade barriers  Article I of GATT – Most Favored Nation (MFN)  Article II of GATS - MFN 

Economic growth, debt and inequality

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

Chapter 2 – Global Transitions

WTO and medicines: from Doha to Cancún

Intellectual Property Protection and Access to Medicines

WIPO NATIONAL SEMINAR ON INTELLECTUAL PROPERTY RIGHTS AND THE PROTECTION OF PHARMACEUTICAL PRODUCTS Damascus, April 25 and 26, 2005 Current issues on Intellectual.

Trade-related policies and access to medicines

Competing in Global Markets

Presentation transcript:

A revised framework for global medicine access Sanjay Basu Reblaw X

The pipeline R&D Better treatment outcomes Market failure Lack of financing Monopoly pricing of medicines & tech Infrastructure inadequacy Social support & Adherence difficulties

Price v. production cost of key AIDS drugs Source: HMS, 2002

R&D spending? Source: Securities & Exchange Commission, 2003

Source: Jim Kim, Harvard Medical School, 2001

Source: Univ of Minnesota, 2001

World Pharmaceutical Market Source: IMS Health, 2002 Region% of market North America41.80% EU24.8 Japan11.3 L. America/Caribbean7.5 SE Asia5.0 Middle East2.6 E. Europe1.8 India1.8 Africa1.3

Rhetoric v. Reality TRIPs & the WTO Parallel importation –cross-border trade of patented goods Compulsory licensing –generic production, primarily for domestic market Special 301

What generics can help do… Source: Oxfam, 2003

The Doha Declaration “We recognize that WTO members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement.”

Information onslaught... PhRMA budget: $150 million/year $1 million for an "intellectual echo chamber of economists” $2.5 million in payments to research and policy organizations "to build intellectual capital” $17.5 million to fight price controls and protect patent rights in foreign countries and in trade negotiations $9.4 million for public relations Source: NYTimes, 1 June 2003

Intellectual echo chamber... Attaran and “off-patent essential medicines” Roger Bate and “Africa Fighting Malaria” DiMasi’s “$800 million” R&D figure Data exclusivity, diversion Source: Public Citizen, 2001

Post-Doha: USTR (originally with EU and Japanese support) broke initial deadline for negotiations 17-page decision Possible implementation by Canada?

The new USTR proposals: Chile – CAFTA – ARTA – FTAA – PPP Singapore – Indonesia/Thailand – ASEAN SACU

Positive trends... New infrastructure being built in southern Africa by Brazil March-ins through Bayh-Dole: Norvir Expansion beyond AIDS and into the United States: Xalatan glaucoma case Pooled R&D approach ( ) New non-market approaches: DNDi

More information… Dying for Growth: Global Inequality and the Health of the Poor (Kim et al., 2000) Pathologies of Power: Health, Human Rights and the New War on the Poor (Farmer, 2003) The Political Economy of Social Inequalities: Consequences for Health & Quality of Life (Navarro, 2002) Global Intellectual Property Rights: Knowledge, Access and Development (Drahos & Mayne, 2002)